She's trying to outrun pancreatic cancer. Breakthrough treatments give her hope
It shows the drug, daraxonrasib, outperforming chemotherapy and enabling patients to live three to four times longer, or eight to nine months without disease progression, on average.
The NPR feature follows Vicky Stinson, a 65‑year‑old pancreatic cancer patient, who has benefited from the newly approved drug daraxonrasib and other experimental therapies, highlighting recent clinical advances in the disease.
Pancreatic cancer remains one of the most lethal cancers with a five‑year survival rate of about 13%. New targeted agents such as daraxonrasib are the first drugs reported to significantly extend progression‑free survival in this setting, potentially transforming treatment and offering hope to patients.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.